KR102669686B1 - 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 - Google Patents

변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 Download PDF

Info

Publication number
KR102669686B1
KR102669686B1 KR1020237002909A KR20237002909A KR102669686B1 KR 102669686 B1 KR102669686 B1 KR 102669686B1 KR 1020237002909 A KR1020237002909 A KR 1020237002909A KR 20237002909 A KR20237002909 A KR 20237002909A KR 102669686 B1 KR102669686 B1 KR 102669686B1
Authority
KR
South Korea
Prior art keywords
amino acid
heterodimer
construct
acid substitutions
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237002909A
Other languages
English (en)
Korean (ko)
Other versions
KR20230019503A (ko
Inventor
마리오 산체스
토마스 스프레터 폰 크로이덴스타인
던야 유로세브
스테이시 에이. 엘. 톰-유
애덤 루이스 코퍼
이고르 에드몬도 파올로 디안젤로
양-지에 추
서지트 비마라오 딕시트
Original Assignee
자임워크스 비씨 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자임워크스 비씨 인코포레이티드 filed Critical 자임워크스 비씨 인코포레이티드
Priority to KR1020247017112A priority Critical patent/KR20240093883A/ko
Priority claimed from KR1020167036436A external-priority patent/KR102493430B1/ko
Publication of KR20230019503A publication Critical patent/KR20230019503A/ko
Application granted granted Critical
Publication of KR102669686B1 publication Critical patent/KR102669686B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020237002909A 2015-04-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도 Active KR102669686B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247017112A KR20240093883A (ko) 2015-04-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562154055P 2015-04-28 2015-04-28
US62/154,055 2015-04-28
KR1020167036436A KR102493430B1 (ko) 2014-05-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
PCT/IB2015/054107 WO2015181805A1 (en) 2014-05-28 2015-05-29 Modified antigen binding polypeptide constructs and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167036436A Division KR102493430B1 (ko) 2014-05-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017112A Division KR20240093883A (ko) 2015-04-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20230019503A KR20230019503A (ko) 2023-02-08
KR102669686B1 true KR102669686B1 (ko) 2024-05-29

Family

ID=58848603

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237002909A Active KR102669686B1 (ko) 2015-04-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
KR1020247017112A Pending KR20240093883A (ko) 2015-04-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247017112A Pending KR20240093883A (ko) 2015-04-28 2015-05-29 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Country Status (3)

Country Link
JP (4) JP7103751B6 (https=)
KR (2) KR102669686B1 (https=)
CN (1) CN106661121A (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP7654539B2 (ja) * 2018-09-07 2025-04-01 ファイザー・インク 抗αｖβ８抗体、組成物及びその使用
AU2019412561A1 (en) * 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
JP7535273B2 (ja) * 2019-04-26 2024-08-16 スアンズ バイオファーマシューティカル カンパニー，リミテッド Ｃｄ８０バリアントタンパク質とその使用
US20250223379A1 (en) * 2021-01-11 2025-07-10 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
CA3217487A1 (en) * 2021-04-23 2022-10-27 Chimagen Biosciences, Ltd Heterodimeric antibodies and antigen-binding fragment thereof
JP2024544607A (ja) * 2021-11-25 2024-12-03 エフ． ホフマン－ラ ロシュ アーゲー 少量の抗体副産物の定量
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082179A1 (en) 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102493430B1 (ko) 2014-05-28 2023-01-31 자임워크스 비씨 인코포레이티드 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
JP2009541275A (ja) * 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
CN107501407B (zh) * 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
DK2786762T3 (da) * 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) * 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BR112013023918A2 (pt) * 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
SG11201401422VA (en) * 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
IN2015DN01299A (https=) * 2012-07-23 2015-07-03 Zymeworks Inc

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082179A1 (en) 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US20150307594A1 (en) 2012-11-28 2015-10-29 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102493430B1 (ko) 2014-05-28 2023-01-31 자임워크스 비씨 인코포레이티드 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도

Also Published As

Publication number Publication date
JP7103751B2 (ja) 2022-07-20
KR20230019503A (ko) 2023-02-08
JP7183221B2 (ja) 2022-12-05
JP2020202848A (ja) 2020-12-24
JP2024125389A (ja) 2024-09-18
CN106661121A (zh) 2017-05-10
KR20240093883A (ko) 2024-06-24
JP7103751B6 (ja) 2022-08-15
JP2023027107A (ja) 2023-03-01
JP2018502550A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
US12286489B2 (en) Modified antigen binding polypeptide constructs and uses thereof
JP6797862B2 (ja) 遺伝子操作された免疫グロブリン重鎖−軽鎖対およびその使用
KR102669686B1 (ko) 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
HK40077442A (en) Modified antigen binding polypeptide constructs and uses thereof
BR122021004365B1 (pt) Constructo de polipeptídeo de ligação de antígeno isolado, composição farmacêutica, métodos para obter o constructo e uso do constructo
BR122021004364B1 (pt) Constructo de polipeptídeo de ligação de antígeno isolado, composição farmacêutica, métodos para obter o constructo e uso do constructo
HK1237351A1 (en) Modified antigen binding polypeptide constructs and uses thereof
BR112015012385B1 (pt) Constructo de polipeptídeo de ligação de antígeno isolado, composição farmacêutica, uso do constructo, métodos para obter o constructo, método para preparar o constructo e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230125

Application number text: 1020167036436

Filing date: 20161227

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230206

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230522

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240222

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240522

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240523

End annual number: 3

Start annual number: 1

PG1601 Publication of registration